List of Excipients in Branded Drug LEADER ALL DAY ALLERGY

Generic Drugs Containing LEADER ALL DAY ALLERGY

Company	Ingredient	NDC	Excipient
Cardinal Health	cetirizine	37205-820	HYPROMELLOSES
Cardinal Health	cetirizine	37205-820	LACTOSE MONOHYDRATE
Cardinal Health	cetirizine	37205-820	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in LEADER ALL DAY ALLERGY?

# Of NDCs	Excipient
1	FD&C BLUE NO. 1
1	HYPROMELLOSE
1	HYPROMELLOSES

LEADER ALL DAY ALLERGY Excipient Strategy and Commercial Opportunities

Last updated: September 13, 2026

Leader All Day Allergy is a private-label cetirizine hydrochloride product positioned in the U.S. over-the-counter allergy market. Its core commercial advantage is low-cost, once-daily antihistamine therapy rather than proprietary active-ingredient protection. The main opportunities are formulation differentiation, price-tier expansion, pediatric and senior-friendly dosage forms, and manufacturing simplification.

What is Leader All Day Allergy?

Leader All Day Allergy is an OTC allergy product containing cetirizine hydrochloride, generally at a 10 mg dose per tablet. Cetirizine is a second-generation H1 antihistamine used for temporary relief of symptoms associated with hay fever, respiratory allergies, and hives.

Leader is a private-label retail brand associated with Cardinal Health’s consumer-healthcare business. Products under the Leader brand may be manufactured by third-party pharmaceutical companies and distributed through retail and institutional channels. The specific manufacturer, NDC, dosage form, and inactive-ingredient profile can vary by product presentation.

Attribute	Product profile
Brand	Leader All Day Allergy
Active ingredient	Cetirizine hydrochloride
Typical strength	10 mg
Therapeutic class	Second-generation antihistamine
U.S. status	OTC
Common dosage form	Film-coated tablet
Primary indication	Allergy symptoms and hives
Prescription patent exposure	No material current patent barrier
Main competitors	Zyrtec, store-brand cetirizine, Claritin, Allegra, Benadryl
Principal commercial channel	Retail pharmacy, mass retail, club, grocery, e-commerce

FDA labeling for cetirizine products identifies the active ingredient, dosing, warnings, and inactive ingredients for each marketed SKU. The applicable DailyMed record should be used for SKU-specific excipient verification because private-label products can change suppliers or formulations without changing the consumer-facing brand name (National Library of Medicine, n.d.).

What excipients are used in Leader All Day Allergy tablets?

The likely excipient architecture for a conventional cetirizine tablet includes a filler, binder, disintegrant, lubricant, glidant, and film-coating system. Exact ingredients must be confirmed against the relevant NDC label.

Common excipient functions are:

Excipient function	Typical materials	Commercial purpose
Diluent	Lactose monohydrate, microcrystalline cellulose	Controls tablet weight and improves compression
Binder	Povidone or pregelatinized starch	Provides mechanical strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes tablet breakup after ingestion
Lubricant	Magnesium stearate	Prevents sticking and supports tablet ejection
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose	Protects the tablet and improves swallowability
Plasticizer	Polyethylene glycol	Improves coating flexibility
Opacifier	Titanium dioxide or equivalent pigment	Provides color and opacity
Surfactant	Sodium lauryl sulfate in some formulations	Supports wetting and processing

The formulation strategy for a low-cost private-label tablet is usually based on established, compendial excipients with broad supplier availability. This reduces qualification costs, limits supply disruption risk, and supports multiple contract manufacturing sites.

How should the excipient strategy be optimized?

Cost control

Cetirizine tablets have a low active-ingredient cost relative to packaging, logistics, retail margin, and quality operations. Excipient savings therefore have limited impact unless they improve manufacturing yield or reduce process complexity.

The highest-value cost levers are:

1. Direct compression instead of wet granulation where powder flow and content uniformity allow it.
2. A single multifunctional filler-binder, such as microcrystalline cellulose.
3. A simplified film-coating system.
4. Reduced tablet weight.
5. Fewer colorants and lower coating-material consumption.
6. Common excipients shared across multiple Leader products.

A direct-compression platform could support cetirizine, loratadine, fexofenadine, and related OTC tablets. Platform reuse reduces scale-up and validation costs.

Manufacturing robustness

Cetirizine tablets must achieve uniform drug distribution, adequate hardness, rapid disintegration, and acceptable dissolution. The formulation should be tested for:

• Blend uniformity
• Tablet weight variation
• Content uniformity
• Friability
• Hardness
• Disintegration
• Dissolution
• Coating defects
• Stability under temperature and humidity stress

Cetirizine hydrochloride is compatible with conventional solid-dose manufacturing, but the formulation still requires control of powder flow, lubrication time, and compression force. Excess magnesium stearate can reduce tablet wetting and slow dissolution. Over-lubrication is therefore a practical process risk.

Consumer acceptability

The main consumer complaints associated with allergy tablets are difficulty swallowing, chalky mouthfeel, strong taste, tablet odor, and confusion over drowsiness warnings. The excipient system can address these issues through:

• Smooth film coating
• Smaller tablet geometry
• Rapid disintegration
• Low-odor packaging
• Dye-free presentation
• Reduced tablet weight
• Chewable or orally disintegrating formats

A standard film-coated tablet is suitable for adult mass-market distribution, but it offers limited differentiation. Consumer-oriented excipient development should focus on the dosage form rather than marginal changes to the conventional tablet core.

What formulations are protected by Leader All Day Allergy patents?

Leader All Day Allergy does not appear to rely on a meaningful proprietary patent estate for its conventional cetirizine tablet. Cetirizine is a mature active ingredient, and standard cetirizine tablets are broadly available from generic and private-label manufacturers.

The relevant intellectual-property position is generally as follows:

IP category	Risk level	Assessment
Cetirizine active ingredient	Low	Mature, off-patent active ingredient
Conventional 10 mg tablet	Low	Multiple generic and private-label equivalents
Standard excipient combination	Low	Routine formulation technology
Film coating	Low	Conventional pharmaceutical coating approach
Packaging configuration	Low to moderate	Trade dress and package design may be protected
ODT or chewable technology	Moderate	May involve formulation or process patents
Combination products	Moderate	Combination-specific patents may apply
Manufacturing process	Low to moderate	Process claims depend on the specific formulation

The absence of a significant patent barrier does not eliminate freedom-to-operate requirements. A new orally disintegrating tablet, taste-masked formulation, extended-release product, or combination product could encounter third-party formulation patents.

When does Leader All Day Allergy lose exclusivity?

Leader All Day Allergy has no meaningful brand exclusivity comparable to a newly approved prescription product. Its commercial protection comes from retail placement, private-label sourcing, pricing, packaging, and consumer recognition.

Cetirizine’s original prescription and OTC market exclusivity periods have expired. The product is therefore exposed to:

• Store-brand substitution
• Retailer switching
• E-commerce price competition
• Pharmacy generic substitution
• Seasonal promotional pressure
• Contract-manufacturer bidding

FDA’s OTC regulatory framework allows compliant allergy products to be marketed under the applicable monograph or other authorized pathway. The current regulatory status depends on the product’s labeling, formulation, dosage form, and manufacturing controls (U.S. Food and Drug Administration, n.d.-a).

What is the Orange Book status of cetirizine?

The Orange Book is principally relevant to approved prescription and certain approved OTC drug applications. It identifies reference listed drugs, therapeutic-equivalence evaluations, and patent or exclusivity information where applicable (U.S. Food and Drug Administration, n.d.-b).

For a conventional private-label cetirizine product:

• Orange Book patent listings are unlikely to create a current market-entry barrier.
• Paragraph IV litigation is not a central risk for routine cetirizine tablets.
• The commercial issue is substitution against other equivalent products, not loss of a protected franchise.
• Any specific Orange Book conclusion must be tied to the product’s NDC and application pathway.

Are there Paragraph IV challenges involving Leader All Day Allergy?

No material Paragraph IV strategy is expected for a mature private-label cetirizine product. Paragraph IV certifications are generally relevant when an ANDA applicant challenges unexpired patents listed for a reference listed drug. A conventional cetirizine tablet is not dependent on a current patent dispute to enter the market.

Paragraph IV exposure could become relevant if a company launches a differentiated cetirizine product that references a newer formulation, delivery technology, combination product, or patented dosage regimen.

What commercial opportunities exist for Leader All Day Allergy?

Dye-free and allergen-positioned products

A dye-free cetirizine tablet could appeal to consumers who avoid artificial colors. A lactose-free version could serve consumers with lactose sensitivity or buyers seeking simplified ingredient labeling. These products would require careful claims control because excipient absence does not support disease or allergy claims by itself.

The opportunity is strongest in e-commerce, pharmacy chains, and retailer-specific wellness programs where product filters expose ingredient attributes.

Orally disintegrating tablets

An orally disintegrating cetirizine tablet could target consumers who have difficulty swallowing conventional tablets. The principal formulation barriers are taste masking, mechanical strength, moisture protection, and packaging cost.

Potential excipient systems include:

• Mannitol for cooling mouthfeel and rapid dissolution
• Crospovidone or low-substituted hydroxypropyl cellulose for disintegration
• Sucralose or another high-intensity sweetener
• Flavor systems
• Polymer-based taste masks
• Moisture-barrier blister packaging

This format could command a higher retail price than a standard tablet, but packaging and stability costs would rise.

Chewable tablets

Chewables provide a pediatric and convenience-oriented line extension. They require stronger taste-masking controls than swallowed tablets because the drug remains in the mouth. The product must also address tablet texture, aftertaste, dose accuracy, and child-resistant packaging requirements.

A chewable product can be commercially attractive, but cetirizine already has broad pediatric availability. Differentiation would depend on taste, price, and retailer distribution.

Liquid formulations

An oral solution or syrup could support pediatric use and consumers unable to swallow tablets. The excipient strategy would need to address:

• Preservative selection
• pH control
• Sweetener system
• Viscosity
• Microbial control
• Measuring-device accuracy
• Sugar-free positioning

A sugar-free liquid may offer a stronger commercial proposition than a conventional syrup. The tradeoff is higher manufacturing complexity and greater stability risk than a tablet.

Combination products

Cetirizine combined with pseudoephedrine could compete in the decongestant-allergy segment. The formulation would face regulatory, labeling, packaging, and abuse-prevention requirements associated with pseudoephedrine. Sales channels may be more restricted, and the product would have a different compliance profile from single-ingredient cetirizine.

A cetirizine-montelukast combination is not a routine OTC opportunity because montelukast is a prescription drug and has significant regulatory and safety considerations.

How does Leader All Day Allergy compare with competing allergy drugs?

Product class	Active ingredient	Main advantage	Excipient opportunity	Competitive pressure
Leader All Day Allergy	Cetirizine	Low price and once-daily dosing	Dye-free, ODT, chewable, liquid	High
Zyrtec	Cetirizine	Brand recognition	Premium packaging and dosage forms	High
Claritin	Loratadine	Often positioned as less sedating	Fast-melt and liquid formats	High
Allegra	Fexofenadine	Non-sedating positioning	High-strength and pediatric formats	High
Benadryl	Diphenhydramine	Familiarity and broad availability	Liquids and chewables	High, with greater sedation concerns

Cetirizine is commercially competitive because it combines once-daily dosing with broad consumer awareness. Its main disadvantage is that some consumers report drowsiness. Excipient changes cannot materially eliminate an active-ingredient safety or tolerability characteristic. Marketing and labeling must remain consistent with FDA requirements.

What generic entry risks exist?

Generic-entry risk is already embedded in the product category. The relevant risks are commercial rather than patent-driven.

Price erosion

Retailers can source equivalent cetirizine products from several suppliers. A new contract manufacturer can pressure pricing without developing new chemistry or complex delivery technology.

Retailer disintermediation

Large retailers increasingly control private-label specifications, supplier qualification, packaging, and promotional placement. A brand owner can lose volume if a retailer changes suppliers or moves to a lower-cost equivalent.

Supply-chain concentration

Reliance on one active-ingredient supplier, one tablet manufacturer, or one coating supplier creates avoidable disruption risk. A dual-source strategy should cover both the active ingredient and finished dosage form.

Seasonal demand volatility

Allergy demand is seasonal and weather-sensitive. Inventory planning must accommodate spring and early summer demand spikes while limiting post-season overstock.

What manufacturing and IP barriers affect new opportunities?

The conventional tablet has low technical barriers. The more defensible opportunities are in dosage forms and consumer-use attributes.

Opportunity	Technical barrier	Regulatory burden	Commercial potential
Standard tablet	Low	Low	High volume, low margin
Dye-free tablet	Low	Low	Moderate
Lactose-free tablet	Low	Low	Moderate
Chewable tablet	Moderate	Moderate	Moderate
ODT	Moderate to high	Moderate	High if taste is acceptable
Pediatric liquid	Moderate	Moderate	Moderate
Combination with pseudoephedrine	Moderate	Higher	Moderate
Extended-release cetirizine	High	High	Uncertain

A formulation patent is more plausible for an ODT, taste-masked product, or novel combination than for a standard film-coated cetirizine tablet. Freedom-to-operate analysis should cover formulation patents, taste-masking systems, orally disintegrating matrices, packaging technologies, and manufacturing processes.

What is the revenue exposure and market outlook?

Leader All Day Allergy revenue is not generally disclosed as a standalone product line. Revenue exposure should therefore be estimated through:

• Retailer distribution count
• Unit velocity by channel
• Pack size
• Wholesale acquisition price
• Seasonal sell-through
• Promotion frequency
• Share of the broader private-label cetirizine category

The standard tablet is likely a high-volume, low-margin product. Premium growth is more likely from differentiated formats than from the base tablet. The most commercially attractive sequence is:

1. Maintain the low-cost 10 mg tablet.
2. Add a dye-free or lactose-free variant.
3. Develop an ODT or chewable product.
4. Add a pediatric liquid if retailer demand supports the manufacturing investment.
5. Evaluate combination products only after regulatory and channel constraints are quantified.

Key Takeaways

• Leader All Day Allergy is a mature private-label cetirizine product with limited patent-based exclusivity.
• The conventional tablet should use widely available, compendial excipients and a manufacturing platform shared across OTC allergy products.
• The most useful excipient innovations concern taste, disintegration, tablet size, coating, and preservative-free or sugar-free positioning.
• ODT, chewable, liquid, dye-free, and lactose-free versions offer the clearest commercial extensions.
• Paragraph IV litigation and biosimilar risk are not material for the conventional cetirizine product.
• The principal risks are price erosion, retailer switching, seasonal inventory volatility, and third-party supply dependence.
• A differentiated dosage form may create greater margin and defensibility than further optimization of the standard tablet.

FAQs

Is Leader All Day Allergy the same as Zyrtec?

Both products can contain cetirizine hydrochloride at the same strength, but they may differ in manufacturer, inactive ingredients, packaging, price, and regulatory listing.

Can Leader All Day Allergy be reformulated as an orally disintegrating tablet?

Yes. The key development issues are taste masking, rapid disintegration, mechanical strength, moisture control, and packaging stability.

Is lactose-free cetirizine commercially attractive?

It can be attractive as a retailer-specific or e-commerce product, particularly where ingredient filters and dietary-positioning claims influence purchasing. The claim must match the validated formulation and labeling.

Does cetirizine have biosimilar competition?

No. Cetirizine is a small-molecule drug, not a biologic. Biosimilar regulation does not apply.

What is the strongest patent opportunity for a new cetirizine product?

The strongest potential patent position would likely involve a genuinely differentiated delivery system, such as a taste-masked ODT, novel liquid-stability system, or specialized combination product. A conventional tablet with routine excipients is unlikely to support meaningful patent exclusivity.

References

1. National Library of Medicine. (n.d.). DailyMed: Cetirizine hydrochloride drug labels. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-a). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (n.d.-c). Inactive ingredient database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download

5. U.S. Food and Drug Administration. (n.d.-d). OTC Monograph Reform under the CARES Act. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/otc-monograph-reform-cares-act